,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Mr. Howard W. Robin', 'age': 69, 'title': 'CEO, Pres & Director', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 1834165, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
1,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Mr. Mark A. Wilson', 'age': 50, 'title': 'Sr. VP, Chief Legal Officer & Sec.', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 749993, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
2,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Dr. Jonathan  Zalevsky Ph.D.', 'age': 47, 'title': 'Sr. VP & Chief R&D Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 1246371, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
3,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Ms. Sandra A. Gardiner', 'age': 56, 'title': 'Chief Financial Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
4,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Vivian  Wu', 'title': 'Director of Investor Relations & Corp. Affairs', 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
5,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Mr. Robert  Bacci', 'title': 'Sr. VP of HR & Facilities Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
6,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Ms. Jennifer  Ruddock', 'title': 'Chief Bus. Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
7,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Dr. Mary  Tagliaferri L.Ac., M.D.', 'age': 56, 'title': 'Chief Medical Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
8,455 Mission Bay Boulevard South,San Francisco,CA,94158,United States,415 482 5300,415 339 5300,https://www.nektar.com,Biotechnology,Healthcare,"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.",216,"{'maxAge': 1, 'name': 'Dr. Loui  T. Madakamutil', 'title': 'VP and Head of Discovery & Research', 'exercisedValue': 0, 'unexercisedValue': 0}",9,7,8,2,6,1693526400,1672444800,86400,4,0.6666,0.68,0.68,0.7315,0.6666,0.68,0.68,0.7315,0.0,1.0,-1.1203175,3356844,3356844,7038116,2220160,2220160,0.69,0.71,1400,800,134185992,0.51,4.37,1.5293419,0.6474,1.3164,0.0,0.0,USD,-157948896,0.0,141815222,190119008,6776995,5799439,1690761600,1693440000,0.0356,0.010670001,0.97383004,0.53,0.0735,1.036,0.6812741,1672444800,1703980800,1688083200,-306876992,-1.57,-0.63,0.07,2:1,966988800,-1.8,1.136,NMS,EQUITY,NKTR,NKTR,Nektar Therapeutics,Nektar Therapeutics,767971800,America/New_York,EDT,-14400000,0.7058,6.0,0.6,2.42,1.5,3.1,hold,5,409432000,2.154,-139094000,124750000,8.103,8.7,87741000,63.338,0.465,-0.13771,-0.93604,70420000,-96385504,-244028000,-0.05,0.71212,-1.58528,-1.70298,USD,
